Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology use… Read more
Bone Biologics Corp (BBLG) - Net Assets
Latest net assets as of September 2025: $6.02 Million USD
Based on the latest financial reports, Bone Biologics Corp (BBLG) has net assets worth $6.02 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.35 Million) and total liabilities ($334.28K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.02 Million |
| % of Total Assets | 94.74% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 29.12 |
Bone Biologics Corp - Net Assets Trend (2012–2024)
This chart illustrates how Bone Biologics Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bone Biologics Corp (2012–2024)
The table below shows the annual net assets of Bone Biologics Corp from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $3.48 Million | +19.86% |
| 2023-12-31 | $2.91 Million | -51.13% |
| 2022-12-31 | $5.95 Million | -9.55% |
| 2021-12-31 | $6.58 Million | +148.02% |
| 2020-12-31 | $-13.69 Million | -15.38% |
| 2019-12-31 | $-11.87 Million | -38.02% |
| 2018-12-31 | $-8.60 Million | -2.41% |
| 2017-12-31 | $-8.40 Million | +2.76% |
| 2016-12-31 | $-8.63 Million | -51.98% |
| 2015-12-31 | $-5.68 Million | -53.60% |
| 2014-12-31 | $-3.70 Million | +34.05% |
| 2013-12-31 | $-5.61 Million | -119843.32% |
| 2012-12-31 | $-4.68K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bone Biologics Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8501484700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.95K | 0.08% |
| Other Components | $88.50 Million | 2540.49% |
| Total Equity | $3.48 Million | 100.00% |
Bone Biologics Corp Competitors by Market Cap
The table below lists competitors of Bone Biologics Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SOUTHERN EMPIRE RES.CORP.
F:5RE
|
$2.22 Million |
|
Vogiatzoglou Systems S.A
AT:VOSYS
|
$2.22 Million |
|
capsensixx AG
XETRA:CPX
|
$2.22 Million |
|
0QDW
LSE:0QDW
|
$2.22 Million |
|
Social Life Network Inc
PINK:WDLF
|
$2.22 Million |
|
WESTERN DIGITAL - Dusseldorf Stock Exchang
DU:WDC
|
$2.22 Million |
|
VANZO
KLSE:0333
|
$2.21 Million |
|
Resource Development Group Ltd
AU:RDG
|
$2.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bone Biologics Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,906,361 to 3,483,657, a change of 577,296 (19.9%).
- Net loss of 4,112,000 reduced equity.
- Dividend payments of 3,212,504 reduced retained earnings.
- New share issuances of 2,616,315 increased equity.
- Other factors increased equity by 5,285,485.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.11 Million | -118.04% |
| Dividends Paid | $3.21 Million | -92.22% |
| Share Issuances | $2.62 Million | +75.1% |
| Other Changes | $5.29 Million | +151.72% |
| Total Change | $- | 19.86% |
Book Value vs Market Value Analysis
This analysis compares Bone Biologics Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.54x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.00 | $1.24 | x |
| 2013-12-31 | $-1.12 | $1.24 | x |
| 2014-12-31 | $-8904.80 | $1.24 | x |
| 2015-12-31 | $-7185.58 | $1.24 | x |
| 2016-12-31 | $-8003.54 | $1.24 | x |
| 2017-12-31 | $-7766.72 | $1.24 | x |
| 2018-12-31 | $-6159.15 | $1.24 | x |
| 2019-12-31 | $-232.07 | $1.24 | x |
| 2020-12-31 | $-267.75 | $1.24 | x |
| 2021-12-31 | $152.47 | $1.24 | x |
| 2022-12-31 | $124.95 | $1.24 | x |
| 2023-12-31 | $11.05 | $1.24 | x |
| 2024-12-31 | $2.30 | $1.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bone Biologics Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -118.04%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.11x
- Recent ROE (-118.04%) is below the historical average (-36.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-247.40 |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-521.19K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.05 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.31 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-25.04 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.21 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.57 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.24 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-455.46K |
| 2021 | -24.50% | 0.00% | 0.00x | 1.02x | $-2.27 Million |
| 2022 | -24.96% | 0.00% | 0.00x | 1.43x | $-2.08 Million |
| 2023 | -307.91% | 0.00% | 0.00x | 1.29x | $-9.24 Million |
| 2024 | -118.04% | 0.00% | 0.00x | 1.11x | $-4.46 Million |
Industry Comparison
This section compares Bone Biologics Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bone Biologics Corp (BBLG) | $6.02 Million | 0.00% | 0.06x | $2.22 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |